This site is only for use by healthcare professionals. By continuing to view this site you are confirming that you are a healthcare professional.

Key Opinions in Medicine

Home
Issues
About
Contact
Register
Login

fig7

Published December 7, 2017 at 690 × 392 in MONALEESA-2 supports the evolving role of CDK4/6 inhibitors in addition to standard therapy for postmenopausal women with HR-positive, HER2- negative advanced breast cancer.

← Previous Next →

Figure 7. Overall response rate (ribociclib + letrozole vs placebo + letrozole) by geographical region9. Adapted from:
Yap YS, et al. ESMO Asia 2016. Abstract LBA1.

Popular Issues

Konkurrenz für den Therapiestandard

MOVICOL® (PEG3350 plus electrolytes): 20 years of evidence-based use

Register

Sign up for free access to Wiley’s Key Opinions in Medicine to keep up to date with latest trends and key developments within your specialty area.

Web design and marketing agency Leamington Spa